One of the strongest biotechs out there, a diamond in the rough, and a high-risk, high-reward play make up the three biotech stocks identified by the author of today’s article as top picks for 2021 for investors looking for even better biotech returns than those offered by broad biotech ETFs such as the SPDR S&P Biotech ETF. For a look…
While many are hopeful that 2021 will bring better times than 2020, there’s much we don’t know about what this new year has in store. One thing we do know, points out the author of today’s article, is that “there will be new problems needing more tech, and tech investors are ever-ready to pounce when that time comes.” As such,…
While the most important decisions made by the FDA in December were undoubtedly the Emergency Use Authorizations for two COVID-19 vaccines, the month also saw a number of firsts on the regulatory front, including the authorization of the first test allowing for at-home collection of patient samples to detect both COVID-19 and influenza A and B. Now, today’s article takes…
Noting how difficult it can be for investors to understand what’s happening in the biotech industry generally and at specific biotech companies, the author of today’s article explains that he tends to invest “in companies that have a track record of working with existing products while successfully developing pipelines of new products” and in “picks-and-shovels companies that get paid to…
While the pharma/biotech sector was not spared COVID-19 pain this year, with various companies hit hard by disruptions in clinical studies and delays in elective surgeries and in individuals seeking medical care, the authors of today’s article note that “some biotech stocks have more than doubled during this period, especially those focusing on developing a coronavirus vaccine.” They proceed to…
Compelling clinical trial data and decisions from the FDA could send one, two, or all three of the biotech stocks highlighted in today’s article through the roof next year. For a look at each of these three biotech stocks and their respective catalysts – as well as a consideration of the potential pitfalls associated with each of them – CLICK…
Biotech bulls see a bright year ahead for the sector thanks to a range of catalysts outside of COVID. As today’s article explains, “Among the most closely tracked catalysts are the potential approval of Biogen Inc.’s experimental drug for Alzheimer’s disease, expectations for a rebound in deal-making activity, and innovations from gene therapy updates to next-generation cancer technologies.” For more…
“In light of all the focus on a coronavirus vaccine, most people tend to overlook the other happenings in the industry,” notes the author of today’s article. He reminds us that, even in the midst of a global pandemic, research has continued on treatments and drugs for cancers, genetic diseases, rare diseases and more – and he highlights three biotech…
“With multiple potential blockbusters in development, and a track record that proves the company knows how to launch a new drug… [this] stock is probably worth the risk right now,” advises the author of today’s article in regards to the biotech he examines, which, having just launched its first rare disease drug last spring, could receive its fourth new drug…
While the small biotech company featured in today’s article is not working on solving the health problem of the day – COVID-19 – it is solving a major problem that affects one in eight couples and is more prevalent than diabetes, asthma and depression. And with the company having “a clear-cut mission, great management, and a history of revenue growth”,…